Table 1.
Characteristics of Hodgkin lymphoma (HL) patients (N = 12,492) by age at diagnosis and neighborhood socioeconomic status (SES) group, California, 1988-2006.
| Characteristic | Age 15 – 44 years | Age ≥ 45 years | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 8228 |
n = 4264 |
|||||||||
| Lower-SES (Quintiles 1-3) |
Higher-SES (Quintiles 4,5) |
Lower-SES (Quintiles 1-3) |
Higher-SES (Quintiles 4,5) |
|||||||
| n=4408 | % | n=3820 | % | P-value | n=2325 | % | n=1939 | % | P-value | |
| Sex | ||||||||||
| Male | 2322 | 52.7 | 1961 | 51.3 | 1326 | 57.0 | 1104 | 56.9 | ||
| Female | 2086 | 47.3 | 1859 | 48.7 | 0.22 | 999 | 43.0 | 835 | 43.1 | 0.95 |
| Year of diagnosis | ||||||||||
| 1988-1992 | 1190 | 27.0 | 1113 | 29.1 | 526 | 22.6 | 471 | 24.3 | ||
| 1993-1997 | 1131 | 25.7 | 969 | 25.4 | 581 | 25.0 | 476 | 24.6 | ||
| 1998-2002 | 1119 | 25.4 | 937 | 24.5 | 630 | 27.1 | 553 | 28.5 | ||
| 2003-2006 | 968 | 22.0 | 801 | 21.0 | 0.18 | 588 | 25.3 | 439 | 22.6 | 0.16 |
| Race/ethnicity | ||||||||||
| Non-Hispanic White | 2551 | 57.9 | 3033 | 79.4 | 1426 | 61.3 | 1578 | 81.4 | ||
| Black | 407 | 9.2 | 128 | 3.4 | 172 | 7.4 | 53 | 2.7 | ||
| Hispanic | 1284 | 29.1 | 407 | 10.7 | 624 | 26.8 | 198 | 10.2 | ||
| Asian/Pacific | 166 | 3.8 | 252 | 6.6 | <0.01 | 103 | 4.4 | 11 | 5.7 | <0.01 |
| Stage | ||||||||||
| I | 606 | 13.8 | 568 | 14.9 | 435 | 18.7 | 397 | 20.5 | ||
| II | 1982 | 45.0 | 1880 | 49.2 | 581 | 30.5 | 592 | 30.5 | ||
| III/IV | 1543 | 35.0 | 1155 | 30.2 | 1102 | 47.4 | 818 | 42.2 | ||
| Missing/unknown | 277 | 6.3 | 217 | 5.7 | <0.01 | 207 | 8.9 | 132 | 6.8 | <0.01 |
| B Symptoms | ||||||||||
| No | 1425 | 32.3 | 1503 | 39.4 | 679 | 29.2 | 682 | 35.2 | ||
| Yes | 1525 | 34.6 | 1222 | 32.0 | 817 | 35.1 | 654 | 33.7 | ||
| Missing/unknown | 1458 | 33.1 | 1095 | 28.7 | <0.01 | 829 | 35.7 | 603 | 31.1 | <0.01 |
| Histologic subtype | ||||||||||
| Nodular sclerosis | 3243 | 73.6 | 3027 | 79.2 | 990 | 42.6 | 939 | 48.4 | ||
| Mixed cellularity | 531 | 12.1 | 376 | 9.8 | 666 | 28.7 | 491 | 25.3 | ||
| Lymphocyte depletion | 61 | 1.4 | 27 | 0.7 | 111 | 4.8 | 59 | 3.0 | ||
| Lymphocyte rich | 123 | 2.8 | 81 | 2.1 | 113 | 4.9 | 84 | 4.3 | ||
| Not otherwise specified | 450 | 10.2 | 309 | 8.1 | <0.01 | 445 | 19.1 | 366 | 18.9 | <0.01 |
| First course of treatment | ||||||||||
| Combined modality | 1409 | 32.0 | 1535 | 40.2 | 299 | 12.9 | 399 | 20.6 | ||
| Radiation only | 514 | 11.7 | 570 | 14.9 | 261 | 11.2 | 269 | 13.9 | ||
| Chemotherapy only | 2010 | 45.6 | 1367 | 35.8 | 1262 | 54.3 | 957 | 49.4 | ||
| None | 475 | 10.8 | 348 | 9.1 | <0.01 | 503 | 21.6 | 314 | 16.2 | <0.01 |
| Vital status | ||||||||||
| Alive | 3681 | 83.5 | 3398 | 89.0 | 958 | 41.2 | 958 | 49.4 | ||
| Death from HL | 402 | 9.1 | 226 | 5.9 | 600 | 25.8 | 410 | 21.1 | ||
| Death from Non-Hodgkin lymphoma or leukemia |
66 | 1.5 | 24 | 0.6 | 172 | 7.4 | 129 | 6.7 | ||
| Death from other cancer | 34 | 0.8 | 27 | 0.7 | 110 | 4.7 | 91 | 4.7 | ||
| Death from circulatory disease |
42 | 1.0 | 24 | 0.6 | 186 | 8.0 | 107 | 5.5 | ||
| Death from other cause | 104 | 2.4 | 82 | 2.2 | 217 | 9.3 | 179 | 9.2 | ||
| Death from unknown cause |
79 | 1.8 | 39 | 1.0 | <0.01 | 82 | 3.5 | 65 | 3.4 | <0.01 |